|1.39|| +0.03 / +2.21%|
Neptune Technologies & Bioresources, Inc. is a biotechnology company engaged primarily in the development and commercialization of marinederived omega-3 polyunsaturated fatty acids (''PUFAs''). It has a patented process of extracting oils from Antarctic krill and principally sells omega-3 PUFAs as bulk oil to company's distributors who commercialize them under their private label primarily in the U.S., European and Australian nutraceutical markets. Neptune's products generally come in capsule form and serve as a dietary supplement to consumers. Through its subsidiaries Acasti Pharma and NeuroBioPharm focuses on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti's prescription drug candidate is CaPre, a purified high omega-3 phospholipid concentrate derived from Neptune krill oil being developed to address the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, which is characterized by abnormally high levels of triglycerides. The company was founded by Henri Harland on October 9, 1998 and is headquartered in Laval, Canada.
|Jim Hamilton||President & Chief Executive Officer|
|Wael Massrieh||Vice President-Scientific Affairs|
|Fotini Sampalis||Chief Global Strategic Officer|
|Michel Timperio||Vice President-Global Sales|
|Jacqueline Khayat||Sales Director|